Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
Authors:
- Mario A. EisenbergerMEMario A. Eisenberger
- Anne-Claire Hardy-BessardAHAnne-Claire Hardy-Bessard
- Loic MoureyLMLoic Mourey
- Paul N. MainwaringPMPaul N. Mainwaring
- Jeremy David ShapiroJSJeremy David Shapiro
- Joan CarlesJCJoan Carles
- Thierry GilTGThierry Gil
- Boris AlekseevBABoris Alekseev
- Sergey IvanovSISergey Ivanov
- 20 May 2012
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (15_suppl) , TPS4692